Skip to main content

Advertisement

You are viewing the new article page. Let us know what you think. Return to old version

Review | Open | Published:

How much do we know about the coupling of G-proteins to serotonin receptors?

Abstract

Serotonin receptors are G-protein-coupled receptors (GPCRs) involved in a variety of psychiatric disorders. G-proteins, heterotrimeric complexes that couple to multiple receptors, are activated when their receptor is bound by the appropriate ligand. Activation triggers a cascade of further signalling events that ultimately result in cell function changes. Each of the several known G-protein types can activate multiple pathways. Interestingly, since several G-proteins can couple to the same serotonin receptor type, receptor activation can result in induction of different pathways. To reach a better understanding of the role, interactions and expression of G-proteins a literature search was performed in order to list all the known heterotrimeric combinations and serotonin receptor complexes. Public databases were analysed to collect transcript and protein expression data relating to G-proteins in neural tissues. Only a very small number of heterotrimeric combinations and G-protein-receptor complexes out of the possible thousands suggested by expression data analysis have been examined experimentally. In addition this has mostly been obtained using insect, hamster, rat and, to a lesser extent, human cell lines. Besides highlighting which interactions have not been explored, our findings suggest additional possible interactions that should be examined based on our expression data analysis.

Introduction

In normal physiology, the neurotransmitter serotonin (5-hydroxytryptamine, 5-HT) and its receptors regulate behaviours such as aggressiveness, anxiety, sex, sleep, mood, learning, cognition and memory. They are involved in numerous disease states, including depression, anxiety, social phobia, schizophrenia, mania, autism, drug addiction, obesity, obsessive-compulsive, panic and eating disorders. Therefore serotonin receptors are the target of a variety of pharmaceutical drugs. With the exception of the 5-HT3 receptor, a ligand-gated ion channel, serotonin receptors are a group of membrane-bound G-protein-coupled receptors, which, by means of G-proteins, activate intracellular pathways to produce an excitatory or inhibitory response [[1]].

G-proteins are heterotrimers consisting of three subunits: Gα, Gβ and Gγ; they are located on the inner plasma membrane, from which they induce GPCR activation. The Gβ and Gγ subunits form an inseparable complex, the βγ complex [[2]]. In the absence of receptor stimulation the Gα subunit binds guanosine diphosphate (GDP) and the βγ complex, and remains dissociated from the receptor. Binding of the ligand to the GPCR domain outside the cell induces conformational changes of the intracellular GPCR domain, giving rise to GPCR coupling to the G heterotrimer. Consequently, the Gα protein exchanges GDP for guanosine triphosphate (GTP), causing dissociation of the GTP-bound α-subunit from the βγ complex and their separation from the activated receptor. Gα and βγ therefore activate a cascade of further signalling events that finally result in a change in cell function. The process is terminated with GTP hydrolysis to GDP by Gα [[3]].

Various Gα families have been described: they can activate different pathways or even exert opposite effects on the same pathway. In general, the 5-HT1 (1A, 1B, 1D, 1E, 1F) receptor family and 5-HT5 receptors couple with Gαi/o protein family to inhibit adenylate ciclase (AC) activity, reducing the intracellular cyclic adenosine monophosphate (cAMP) level whilst the Gαs family 5-coupled to HT4, 5-HT6 and 5-HT7 receptors triggers a pathway that leads to AC activation and cAMP production. The 5-HT2 (2A, 2B, 2C) receptor family couple with Gαq/11 proteins and stimulate the activity of phospholipase C (PLC) increasing the intracellular inositol trisphosphate (IP3), diacyl-glycerol (DAG) and Ca2+ levels [[1]]. However Gαq can also indirectly alter cAMP production, by decreasing Gαs protein abundance [[4]] or by activating adenylate cyclase 8 (ADCY8) by the PLC/Ca2+/calmodulin pathway [[5]]. Moreover, the Gαi/o family induces a decrease in intracellular cAMP levels through AC inhibition.

The Gβ and Gγ subunits are closely associated forming a βγ complex that can be separated only by denaturation, except in cases when the complex involves β5, whose bond to γ subunits is much weaker. At variance with previous studies, the βγ complex does not remain inert after dissociation from the α subunit, but plays a key role both in the inactive and in the active receptor state [[6]]. The βγ complex has the following functions: i) it is required for optimal receptor-G-protein interaction, because it enhances ligand affinity and receptor-G-protein coupling, hence G-protein activation [[7]]; ii) its subunit composition affects receptor-G-protein coupling specificity [[8],[9]]; iii) it activates specific pathways regardless of the type of Gα subunit involved [[10]]. The role of γ subunits is to transport the βγ complex from the endoplasmic reticulum to the plasma membrane. Although all γ proteins share this property, translocation kinetics differs widely among subunits, ranging from 10 sec of the fastest, γ9, to several minutes of the slowest, γ3 [[11]]. It may be hypothesized that the γ subunits allowing fast translocation are associated with human serotonin receptors with a quicker turnover.

Review

Many G-protein isoforms, huge number of possible heterotrimers

We have explored UniProt (http://www.uniprot.org) and Entrez Gene (http://www.ncbi.nlm.nih.gov/gene) databases to establish how many protein isoforms are currently known for each G-protein subtype (Table 1). For example, we have found 10 isoforms of the Gαi2 subtype. Generally, the isoforms do not derive from new gene loci but from different gene expression regulation of the main transcript. In particular, they are due to alternative splicing, use of alternative transcription start sites (TSS) and alternative start codons. All these detailed data are reported in Additional file 1 along with some annotations. In brief, we found many more protein isoforms than expected: Gα, Gβ, and Gγ proteins may actually be as many as 53, 38, and 20, respectively, raising the potential heterotrimers to about 40,000 combinations. Most of the isoforms we reported are shorter and lack one or more functional domains compared to the reference isoforms, so they could have a reduced functional activity. In particular, the shorter Gα subtype isoforms lack GTP domains, the Gβs lack WD domains whereas the Gγs have no alterations lying in their functional domains. Surprisingly, up till now, many isoforms have not yet been confirmed at protein level according to UniProt, so we looked for this information in the literature. Unfortunately, the papers merely report the name of the investigated G-protein and do not specify its particular isoform. We also found nomenclature inaccuracies, which are probably due to the former names of G-protein: for example when the authors write “the Gαq protein” it is unclear whether they mean GNAQ (Gαq) or the entire family including also GNA11 (Gαq11), GNA14 (Gαq14), or GNA15 (Gαq15 also Gαq16); similarly, “Gαi protein” may indicate GNAI1 (Gαi1), GNAI2 (Gαi2), or GNAI3 (Gαi3). The same applies to “Gβγ” [[12]]. The nomenclature is not univocal even in some databases. For example, in UniProt GNG8 is also called GNG9, and GNGT2 is also called GNG8 or GNG9; therefore a paper examining GNG9 could refer either to GNG8 or to GNGT2. To overcome this ambiguity, the authors should indicate the protein or gene identifier or protein sequence.

Table 1 G-protein isoforms

How heterotrimer composition affects 5-HT receptor behaviour

The mechanisms underpinning formation of one heterotrimer rather than another are poorly understood, but post-translational modifications of G-proteins and of membrane environments are likely to be involved [[14]]. Nonetheless heterotrimer composition is critical, because it determines what pathway is activated. For example, activation of 5-HT1A receptor inhibits basal phosphoinositide hydrolysis in the dorsal raphe nucleus but not in the hippocampus, most likely due to different heterotrimer compositions in the two tissues [[15]]. Moreover a single heterotrimer can activate multiple pathways simultaneously, because some Gα proteins have multiple effects. For example, some Gαi/o family proteins inhibit AC leading to intracellular cAMP reduction, whereas others can also inhibit Ca2+ or activate K+ channels [[16]]. To complicate matters further, the same serotonin receptor can couple to different heterotrimers [[7],[17],[18]]; the same ligand may therefore simultaneously activate multiple pathways but be unable to regulate a specific one. The mechanism appears to be irrational, since a single switch (receptor) is unlikely to be able to control a large number of lights (pathways).

Ligand-receptor binding affinity affects G-protein-receptor affinity and vice versa, as described in Spodoptera frugiperda Sf9 cells [[7]]. Such affinity also depends on heterotrimeric composition; for example, coupling of Gαi3 to 5-HT1A or 5-HT1B receptor was more effective than that of Gαi2 and Gαo in enhancing agonist [3H]-5-HT affinity [[14]].

Since a variety of psychiatric disorders and/or drug responses are held to be related to altered ligand-receptor affinity, association studies have mainly explored receptor and downstream effector polymorphisms to explain the genetic basis of such different phenotypes [[19]–[26]]. However, given that G-proteins can affect ligand affinity, their variations should also be considered in association studies. For these reasons it is important to gain insights into the role, the interactors and the expression of G-proteins in determining cell responses as a consequence of receptor activation.

The observations that in some GPCRs the G-protein complex can modulate receptor activity state and that the transition from active to inactive state depends on the Gα subunit associated with the receptor make the study of G-proteins even more intriguing [[14]]. In other words, GPCRs can switch from inactive to active even in the absence of binding to an agonist. This mechanism is still poorly understood and may have important pathological as well as physiological implications. In particular significant activation even without serotonin has been described with coupling of Gαz to 5-HT1A receptor, but not to the other 5-HT1 receptors [[27]].

Finally, a scenario is emerging where different G-protein combinations can bind the same receptor type, conferring a different ligand affinity and activating several pathways. This warrants investigation of the heterotrimeric combinations that may form in humans, their distribution in different tissues, and the differences in ligand binding affinity among the heterotrimers resulting from binding of one receptor type and various G-proteins.

How many couplings between 5-HT receptors and G-proteins are known

In order to find out what is known about heterotrimer associations with serotonin GPCRs, we have performed a literature search. The papers specifically addressing receptor-G-protein complexes were scanty, therefore data were available for quite a small number of complexes out of the possible thousands. Table 2 presents an exhaustive list of all known combinations of the three types of G-proteins and their associations with serotonin receptors in human neural tissues or in similar models. In particular, for each receptor, we have reported the experimentally assessed complexes formed with the G-proteins, the tissues or contexts where the complexes were determined and their references. We have also annotated the couplings assessed as not present along with the particular experimental context. The 5-HT1p and 5-HT3 receptors were excluded, because the former is expressed in the nervous enteric system (not the central nervous system), the latter because it is a serotonin-gated ion channel not coupled to G-proteins, whereas 5-HT5B is a pseudogene in humans according to EntrezGene and the related protein is absent in UniProt.

Table 2 Assessed couplings between G-proteins and serotonin receptors

Many papers have addressed G-protein combinations with 5-HT1A, 5-HT1B, 5-HT2A and 5-HT2C while only one or two papers refer to 5-HT1E, 5-HT1F or 5-HT6. The experimental models usually involve transfection of human genes into Spodoptera frugiperda Sf9 cells, since they express low levels of mammalian G-proteins, thus avoiding competition with endogenously expressed G-proteins in [35S]GTPγS binding assay [[16]].

However, to extend these findings to humans is not necessarily correct. For example, the poor coupling of Gαq to 5-HT1A and 5-HT2C could be due to a large portion of the expressed but inactive Gαq [[84]], maybe because Gαq is not post-translationally modified by palmitoylation in Sf9 as in humans [[85]]. Other authors have used hamster, mouse and human cells transfected with rat, mouse and bovine constructs. The main methods used to assess the compositions of the heterotrimers are immunoprecipitation and western blot analysis, the binding with radio-ligands and FRET (Förster Resonance Energy Transfer) by using fluorescent ligands.

For the majority of serotonergic receptors, coupling data are available only in relation to Gα family proteins without specifying which Gβ and Gγ were coupled. However, the few data on Gβ and Gγ only concerned Gβ1 with Gγ2. Gα proteins coupled to receptors are the most commonly studied G-proteins, because they are held to indicate the pathway activated by receptor stimulation. In contrast, Gβ and Gγ proteins are believed merely to play a structural role, that is to stabilize the receptor complex, but they actively participate in signal transduction by activating specific pathways.

We also annotated the second messengers activated downstream G-proteins, when these data were available in the related paper, since they allow to take into account the converging effect of various Gα proteins and the antagonistic/additive effects of Gβγ.

Investigation methods for the assessment of G-protein activation

We have shown that G-protein heterotrimers recruited by serotonin receptors have been evaluated experimentally. This dearth of data is mainly due to the cumbersome methods used to identify the heterotrimers involved in the effects of ligands and to some technical limitations. In fact, to assess the receptor-mediated G-protein activation, both indirect and direct assays are available [[16]]. Indirect methods, in spite of their good sensitivity, are focused on measuring concentrations of second messengers but the evaluation of these data can be complicated since most receptors can activate different G-proteins.

In particular, since Gαs and Gαi/o proteins activate or inhibit AC respectively, their activation can be indirectly detected determining intracellular adenosine triphosphate (ATP) conversion into cAMP. It is measured using [α-32P]ATP as the enzyme substrate or using cAMP antibodies. These methods cannot follow quick fluctuations as they are based on static measurements after cell lysis. In the case of the AC inhibiting Gαi/o proteins, another problem regards the too low dynamic ranges of inhibition detection. To deal with this specific problem, chimeric Gαi/o proteins were developed, but they do not exactly mimic the natural G-proteins.

To test ligand efficacy on Gαq/11-coupled receptors, [3H]IP3 concentration as product of PLC activity can be measured using [3H]PIP2 (phosphatidyl inositol 4,5-bisphosphate) substrate. Alternatively, antibodies can be used, but, since IP3 has a short half life, it is preferred to detect its stable metabolite inositol-1-phosphate (IP1), although this is a more downstream product. Also Ca2+ concentration, by dyes generating fluorescence upon binding of free Ca2+, can be determined to assess Gαq/11 activation, although these probes can influence calcium levels and kinetics. Moreover, Ca2+-sensitive photoproteins, as aequorin, can detect calcium in specific cell compartments by fusion with targeting sequences. This approach is not so sensitive and consists of laborious procedures, such as fusion protein production, transfection and assay calibration.

Gα12/13 activation can be assessed by determining Rho guanine nucleotide exchange factors (RhoGEFs) by immunoblotting, a not highly sensitive technique. Moreover, since RhoGEFs are activated also by Gαq/11, there are crosstalk problems that can be partially overcome by small interfering RNA (siRNA) knockdown.

To directly and quantitatively assess the Gα protein activation, [35S]GTPγS binding assay is employed. Upon Gα subunit activation, it binds the mimic substrate, so remaining blocked in the active form as it cannot hydrolyze this substrate. The blocked Gα can be measured after isolation and it can be immunoprecipitated to identify the specific Gα subunit. However, this approach is mainly suitable to evaluate Gαi/o-coupled receptor activation. This assay can be effectively combined with the use of drugs stimulating or inhibiting specific G-proteins, for example, Pertussis toxin (PTX), Mastoparan, Mastoparan-S, Cholera toxin, Suramin, Pasteurella multocida toxin (PMT). Alternatively, it is possible to use G-protein-deficient mice or gene silencing by siRNA, although studies have to take into account the cellular compensatory mechanisms that alter the expression level of other G-proteins. An exhaustive review of these and other techniques was made by Denis et al. [[16]].

Moreover, cause of GTPase-accelerating proteins (GAPs) that accelerate GTPase activity of Gα-protein subunits, the measuring of GTPase activity in vivo and in vitro differ. In addition, for in vivo studies, methods having a subsecond time resolution for GTP hydrolysis must be adopted [[86],[87]].

Heterotrimers activation effects

It would be important to consider the synergic effects of the entire activated heterotrimer in order to evaluate ligand effects, drug efficacy and side effects such as hallucination onset. For this reason, we annotated also the second messengers during literature revision. Unfortunately, as can be seen in Table 2, few studies assessed the coupling of all the heterotrimer subunits and few of them assessed the second messengers. Regarding these cases, only Gβ1γ2 were present, so it was not possible to verify if and how different Gβγ combinations can affect Gα induced pathways. In general, the physiological significance of the different Gβγ pairs is unclear, since they participate in complex interactions with receptors, Gα subunits and effectors [[6]].

A more detailed description of the pathway downstream G-proteins was performed by Millan et al. [[88]], however it should be taken into account that the signalling downstream a receptor is ligand-dependent. For example, some agonists of 5-HT2A can induce hallucinations but other structurally related ones do not [[89]].

Expression analysis in human brain tissues

We believe that our collected data can be used for guiding experiments which seek new couplings. However, we verified if it was possible to reduce the number of combinations by filtering out those not allowed in a particular neural tissue due to one or more components that are not expressed. In Additional file 2, we report the expression profiles of Gα, Gβ, Gγ and the serotonin receptor by using three proteomic databases according to a previous work [[90]]: Human Protein Reference Database (http://www.hprd.org); Human Proteinpedia (http://www.humanproteinpedia.org) and Human Protein Atlas (http://www.proteinatlas.org). We also used expression data obtained from three transcriptomic databases: Human Transcriptome Map (http://bioinfo.amc.uva.nl/HTMseq), Cancer Gene Anatomy Project database (http://cgap.nci.nih.gov) and Allen Brain Atlas database (http://www.brain-map.org). An issue that arose in the course of this investigation was the partial conflict between microarray and RNA-Seq data retrieved from Allen Brain Atlas and, to a lesser extent, protein and transcript expression data. Generally, these discrepancies could be resolved by relying on proteomic data, which, if present, are usually more dependable than transcriptomic data. For example, regarding GNG1, it seems to be absent in all tissues and their sub-tissues assessed by Allen Brain Atlas RNA-seq. Instead, according to Allen Brain Atlas microarray data, GNG1 expression results as being very variable among sub-tissues of each tissue. Since in the cerebellar cortex also Protein Atlas data are available, they solve this contradiction claiming GNG1 absence. According to our expression data, most G-proteins are expressed in the majority of brain tissues, thus confirming the possible existence of a big number of heterotrimer combinations in nearly all neural tissues. Of course, co-expression of a receptor and G-proteins in a brain tissue does not imply that they are functionally coupled to each other. However, the available databases, being manually annotated, do not contain the all expression data reported in the literature, so the Additional file 2 may be incomplete.

Conclusion

The large number of human G-proteins that our searches found demonstrates that a very large amount of possible heterotrimers can be formed but unfortunately only a few have been assessed. Naturally, a limitation of the studies carried out in vitro is that the reported couplings do not always match to the couplings found in vivo [[91]]. However, knowledge of all the G-proteins that bind to each receptor would allow linking each receptor to all the possible activated pathways. Association of a receptor with multiple G-proteins would also highlight activation of different pathways in different tissues. This is important, because G-protein gene mutations or polymorphisms could alter transduction efficacy, thus explaining the non-activation of a pathway despite the presence of the right ligand and the absence of nucleotide variation in the receptor. Therefore precise knowledge of the role and distribution of G-proteins would greatly contribute to the evaluation of G-protein gene polymorphisms and to the development of drugs targeting specific G-proteins.

Finally, since receptor binding to a G-protein considerably modifies receptor behaviour, it could be that the G-proteins define many receptor subtypes. For this reason it is more appropriate to consider a receptor not individually but in association to each permitted heterotrimer. This also suggests that a number of experiments should be performed again, like the biochemical studies exploring the affinity constants between ligands and a receptor not considering if, and which, G-proteins were associated.

Additional files

Abbreviations

5-HT:

Serotonin

GPCRs:

G-protein-coupled receptors

GDP:

Guanosine diphosphate

GTP:

Guanosine triphosphate

AC:

Adenylate cyclase

cAMP:

Cyclic adenosine monophosphate

PLC:

Phospholipase C

DAG:

Diacyl-glycerol

IP3:

Inositol trisphosphate

PKC:

Protein kinase C

ADCY8:

Adenylate cyclase 8

TSS:

Transcription start sites

FRET:

Förster resonance energy transfer

ATP:

Adenosine triphosphate

PIP2:

Phosphatidyl inositol 4,5-bisphosphate

IP1:

Inositol-1-phosphate

RhoGEF:

Rho guanine nucleotide exchange factor

siRNA:

Small interfering RNA

PTX:

Pertussis toxin

PMT:

Pasteurella multocida toxin

GAP:

GTPase-accelerating protein

References

  1. 1.

    Filip M, Bader M: Overview on 5-HT receptors and their role in physiology and pathology of the central nervous system. Pharmacol Rep. 2009, 61: 761-777. 10.1016/S1734-1140(09)70132-X.

  2. 2.

    Hurowitz EH, Melnyk JM, Chen YJ, Kouros-Mehr H, Simon MI, Shizuya H: Genomic characterization of the human heterotrimeric G protein alpha, beta, and gamma subunit genes. DNA Res. 2000, 7: 111-120. 10.1093/dnares/7.2.111.

  3. 3.

    Oldham WM, Hamm HE: Heterotrimeric G protein activation by G-protein-coupled receptors. Nat Rev Mol Cell Biol. 2008, 9: 60-71. 10.1038/nrm2299.

  4. 4.

    Tang T, Gao MH, Miyanohara A, Hammond HK: Galphaq reduces cAMP production by decreasing Galphas protein abundance. Biochem Biophys Res Commun. 2008, 377: 679-684. 10.1016/j.bbrc.2008.10.054.

  5. 5.

    Twery EN, Raper JA: SDF1-induced antagonism of axonal repulsion requires multiple G-protein coupled signaling components that work in parallel. PLoS ONE. 2011, 6: e18896-10.1371/journal.pone.0018896.

  6. 6.

    Smrcka AV: G protein betagamma subunits: central mediators of G protein-coupled receptor signaling. Cell Mol Life Sci. 2008, 65: 2191-2214. 10.1007/s00018-008-8006-5.

  7. 7.

    Butkerait P, Zheng Y, Hallak H, Graham TE, Miller HA, Burris KD, Molinoff PB, Manning DR: Expression of the human 5-hydroxytryptamine1A receptor in Sf9 cells. Reconstitution of a coupled phenotype by co-expression of mammalian G protein subunits. J Biol Chem. 1995, 270: 18691-18699. 10.1074/jbc.270.31.18691.

  8. 8.

    Kisselev O, Gautam N: Specific interaction with rhodopsin is dependent on the gamma subunit type in a G protein. J Biol Chem. 1993, 268: 24519-24522.

  9. 9.

    Kleuss C, Scherubl H, Hescheler J, Schultz G, Wittig B: Selectivity in signal transduction determined by gamma subunits of heterotrimeric G proteins. Science. 1993, 259: 832-834. 10.1126/science.8094261.

  10. 10.

    Raymond JR, Mukhin YV, Gettys TW, Garnovskaya MN: The recombinant 5-HT1A receptor: G protein coupling and signalling pathways. Br J Pharmacol. 1999, 127: 1751-1764. 10.1038/sj.bjp.0702723.

  11. 11.

    Ajith Karunarathne WK, O’Neill PR, Martinez-Espinosa PL, Kalyanaraman V, Gautam N: All G protein betagamma complexes are capable of translocation on receptor activation. Biochem Biophys Res Commun. 2012, 421: 605-611. 10.1016/j.bbrc.2012.04.054.

  12. 12.

    Glass M, Northup JK: Agonist selective regulation of G proteins by cannabinoid CB(1) and CB(2) receptors. Mol Pharmacol. 1999, 56: 1362-1369.

  13. 13.

    Wilkie TM, Gilbert DJ, Olsen AS, Chen XN, Amatruda TT, Korenberg JR, Trask BJ, de Jong P, Reed RR, Simon MI, et al: Evolution of the mammalian G protein alpha subunit multigene family. Nat Genet. 1992, 1: 85-91. 10.1038/ng0592-85.

  14. 14.

    Clawges HM, Depree KM, Parker EM, Graber SG: Human 5-HT1 receptor subtypes exhibit distinct G protein coupling behaviors in membranes from Sf9 cells. Biochemistry. 1997, 36: 12930-12938. 10.1021/bi970112b.

  15. 15.

    Johnson RG, Fiorella D, Winter JC, Rabin RA: [3H]8-OH-DPAT labels a 5-HT site coupled to inhibition of phosphoinositide hydrolysis in the dorsal raphe. Eur J Pharmacol. 1997, 329: 99-106. 10.1016/S0014-2999(97)10113-3.

  16. 16.

    Denis C, Sauliere A, Galandrin S, Senard JM, Gales C: Probing heterotrimeric G protein activation: applications to biased ligands. Curr Pharm Des. 2012, 18: 128-144. 10.2174/138161212799040466.

  17. 17.

    Mulheron JG, Casanas SJ, Arthur JM, Garnovskaya MN, Gettys TW, Raymond JR: Human 5-HT1A receptor expressed in insect cells activates endogenous G(o)-like G protein(s). J Biol Chem. 1994, 269: 12954-12962.

  18. 18.

    Parker EM, Grisel DA, Iben LG, Nowak HP, Mahle CD, Yocca FD, Gaughan GT: Characterization of human 5-HT1 receptors expressed in Sf9 insect cells. Eur J Pharmacol. 1994, 268: 43-53. 10.1016/0922-4106(94)90118-X.

  19. 19.

    Piva F, Giulietti M, Armeni T, Principato G: Cross-link immunoprecipitation data to detect polymorphisms lying in splicing regulatory motifs: a method to refine single nucleotide polymorphism selection in association studies. Psychiatr Genet. 2012, 22: 88-91. 10.1097/YPG.0b013e32834c0bd1.

  20. 20.

    Piva F, Giulietti M, Baldelli L, Nardi B, Bellantuono C, Armeni T, Saccucci F, Principato G: Bioinformatic analyses to select phenotype affecting polymorphisms in HTR2C gene. Hum Psychopharmacol. 2011, 26: 365-372.

  21. 21.

    Nardi B, Turchi C, Piva F, Giulietti M, Castellucci G, Arimatea E, Rochetti D, Rocchetti G, Principato G, Tagliabracci A, Bellantuono C: Searching for a relationship between the serotonin receptor 2A gene variations and the development of inward and outward personal meaning organizations. Psychiatr Genet. 2011, 21: 269-270. 10.1097/YPG.0b013e32834371bc.

  22. 22.

    Piva F, Giulietti M, Nardi B, Bellantuono C, Principato G: An improved in silico selection of phenotype affecting polymorphisms in SLC6A4, HTR1A and HTR2A genes. Hum Psychopharmacol. 2010, 25: 153-161. 10.1002/hup.1100.

  23. 23.

    Nardi B, Piva F, Turchi C, Giulietti M, Castellucci G, Arimatea E, Rocchetti D, Rocchetti G, Principato G, Tagliabracci A, Bellantuono C: HTR2A gene polymorphisms and inward and outward personal meaning organisations. Acta Neuropsychiatrica. 2012, 24: 336-343. 10.1111/j.1601-5215.2011.00644.x.

  24. 24.

    Blasi G, De Virgilio C, Papazacharias A, Taurisano P, Gelao B, Fazio L, Ursini G, Sinibaldi L, Andriola I, Masellis R, Romano R, Rampino A, Di Giorgio A, Lo Bianco L, Caforio G, Piva F, Popolizio T, Bellantuono C, Todarello O, Kleinman JE, Gadaleta G, Weinberger DR, Bertolino A: Converging evidence for the association of functional genetic variation in the serotonin receptor 2a gene with prefrontal function and olanzapine treatment. JAMA Psychiatry. 2013, 70: 921-930. 10.1001/jamapsychiatry.2013.1378.

  25. 25.

    Galeazzi R, Massaccesi L, Piva F, Principato G, Laudadio E: Insights into the influence of 5-HT2c aminoacidic variants with the inhibitory action of serotonin inverse agonists and antagonists. J Mol Model. 2014, 20: 2120-10.1007/s00894-014-2120-0.

  26. 26.

    Blasi G, Napolitano F, Ursini G, Di Giorgio A, Caforio G, Taurisano P, Fazio L, Gelao B, Attrotto MT, Colagiorgio L, Todarello G, Piva F, Papazacharias A, Masellis R, Mancini M, Porcelli A, Romano R, Rampino A, Quarto T, Giulietti M, Lipska BK, Kleinman JE, Popolizio T, Weinberger DR, Usiello A, Bertolino A: Association of GSK-3beta genetic variation with GSK-3beta expression, prefrontal cortical thickness, prefrontal physiology, and schizophrenia. Am J Psychiatry. 2013, 170: 868-876. 10.1176/appi.ajp.2012.12070908.

  27. 27.

    Barr AJ, Brass LF, Manning DR: Reconstitution of receptors and GTP-binding regulatory proteins (G proteins) in Sf9 cells. A direct evaluation of selectivity in receptor.G protein coupling. J Biol Chem. 1997, 272: 2223-2229. 10.1074/jbc.272.52.32979.

  28. 28.

    Shenker A, Maayani S, Weinstein H, Green JP: Pharmacological characterization of two 5-hydroxytryptamine receptors coupled to adenylate cyclase in guinea pig hippocampal membranes. Mol Pharmacol. 1987, 31: 357-367.

  29. 29.

    Bertin B, Freissmuth M, Breyer RM, Schutz W, Strosberg AD, Marullo S: Functional expression of the human serotonin 5-HT1A receptor in Escherichia coli. Ligand binding properties and interaction with recombinant G protein alpha-subunits. J Biol Chem. 1992, 267: 8200-8206.

  30. 30.

    Raymond JR, Olsen CL, Gettys TW: Cell-specific physical and functional coupling of human 5-HT1A receptors to inhibitory G protein alpha-subunits and lack of coupling to Gs alpha. Biochemistry. 1993, 32: 11064-11073. 10.1021/bi00092a016.

  31. 31.

    Gettys TW, Fields TA, Raymond JR: Selective activation of inhibitory G-protein alpha-subunits by partial agonists of the human 5-HT1A receptor. Biochemistry. 1994, 33: 4283-4290. 10.1021/bi00180a024.

  32. 32.

    Garnovskaya MN, Gettys TW, van Biesen T, Prpic V, Chuprun JK, Raymond JR: 5-HT1A receptor activates Na+/H+ exchange in CHO-K1 cells through Gialpha2 and Gialpha3. J Biol Chem. 1997, 272: 7770-7776. 10.1074/jbc.272.12.7770.

  33. 33.

    Barr AJ, Manning DR: Agonist-independent activation of Gz by the 5-hydroxytryptamine1A receptor co-expressed in Spodoptera frugiperda cells. Distinguishing inverse agonists from neutral antagonists. J Biol Chem. 1997, 272: 32979-32987. 10.1074/jbc.272.52.32979.

  34. 34.

    Liu YF, Ghahremani MH, Rasenick MM, Jakobs KH, Albert PR: Stimulation of cAMP synthesis by Gi-coupled receptors upon ablation of distinct Galphai protein expression. Gi subtype specificity of the 5-HT1A receptor. J Biol Chem. 1999, 274: 16444-16450. 10.1074/jbc.274.23.16444.

  35. 35.

    Lin SL, Setya S, Johnson-Farley NN, Cowen DS: Differential coupling of 5-HT(1) receptors to G proteins of the G(i) family. Br J Pharmacol. 2002, 136: 1072-1078. 10.1038/sj.bjp.0704809.

  36. 36.

    Albert PR, Sajedi N, Lemonde S, Ghahremani MH: Constitutive G(i2)-dependent activation of adenylyl cyclase type II by the 5-HT1A receptor. Inhibition by anxiolytic partial agonists. J Biol Chem. 1999, 274: 35469-35474. 10.1074/jbc.274.50.35469.

  37. 37.

    Serres F, Li Q, Garcia F, Raap DK, Battaglia G, Muma NA, Van de Kar LD: Evidence that G(z)-proteins couple to hypothalamic 5-HT(1A) receptors in vivo. J Neurosci. 2000, 20: 3095-3103.

  38. 38.

    Malmberg A, Strange PG: Site-directed mutations in the third intracellular loop of the serotonin 5-HT(1A) receptor alter G protein coupling from G(i) to G(s) in a ligand-dependent manner. J Neurochem. 2000, 75: 1283-1293. 10.1046/j.1471-4159.2000.751283.x.

  39. 39.

    Dupuis DS, Wurch T, Tardif S, Colpaert FC, Pauwels PJ: Modulation of 5-HT(1A) receptor activation by its interaction with wild-type and mutant g(alphai3) proteins. Neuropharmacology. 2001, 40: 36-47. 10.1016/S0028-3908(00)00098-8.

  40. 40.

    Newman-Tancredi A, Cussac D, Marini L, Millan MJ: Antibody capture assay reveals bell-shaped concentration-response isotherms for h5-HT(1A) receptor-mediated Galpha(i3) activation: conformational selection by high-efficacy agonists, and relationship to trafficking of receptor signaling. Mol Pharmacol. 2002, 62: 590-601. 10.1124/mol.62.3.590.

  41. 41.

    Slessareva JE, Ma H, Depree KM, Flood LA, Bae H, Cabrera-Vera TM, Hamm HE, Graber SG: Closely related G-protein-coupled receptors use multiple and distinct domains on G-protein alpha-subunits for selective coupling. J Biol Chem. 2003, 278: 50530-50536. 10.1074/jbc.M304417200.

  42. 42.

    Okada M, Goldman D, Linnoila M, Iwata N, Ozaki N, Northup JK: Comparison of G-protein selectivity of human 5-HT2C and 5-HT1A receptors. Ann N Y Acad Sci. 2004, 1025: 570-577. 10.1196/annals.1316.070.

  43. 43.

    la Cour Mannoury C, El Mestikawy S, Hanoun N, Hamon M, Lanfumey L: Regional differences in the coupling of 5-hydroxytryptamine-1A receptors to G proteins in the rat brain. Mol Pharmacol. 2006, 70: 1013-1021. 10.1124/mol.106.022756.

  44. 44.

    Martel JC, Ormiere AM, Leduc N, Assie MB, Cussac D, Newman-Tancredi A: Native rat hippocampal 5-HT1A receptors show constitutive activity. Mol Pharmacol. 2007, 71: 638-643. 10.1124/mol.106.029769.

  45. 45.

    Valdizan EM, Castro E, Pazos A: Agonist-dependent modulation of G-protein coupling and transduction of 5-HT1A receptors in rat dorsal raphe nucleus. Int J Neuropsychopharmacol. 2010, 13: 835-843. 10.1017/S1461145709990940.

  46. 46.

    Rauly-Lestienne I, Lestienne F, Ailhaud MC, Binesse J, Newman-Tancredi A, Cussac D: Competitive interaction of 5-HT(1A) receptors with G-protein subtypes in CHO cells demonstrated by RNA interference. Cell Signal. 2011, 23: 58-64. 10.1016/j.cellsig.2010.08.002.

  47. 47.

    Bae H, Anderson K, Flood LA, Skiba NP, Hamm HE, Graber SG: Molecular determinants of selectivity in 5-hydroxytryptamine1B receptor-G protein interactions. J Biol Chem. 1997, 272: 32071-32077. 10.1074/jbc.272.51.32071.

  48. 48.

    Bae H, Cabrera-Vera TM, Depree KM, Graber SG, Hamm HE: Two amino acids within the alpha4 helix of Galphai1 mediate coupling with 5-hydroxytryptamine1B receptors. J Biol Chem. 1999, 274: 14963-14971. 10.1074/jbc.274.21.14963.

  49. 49.

    Alberts GL, Pregenzer JF, Im WB, Slightom JL: Cloning of serotonin 5-HT(1) receptor subtypes from the chimpanzee, gorilla and Rhesus monkey and their agonist-induced guanosine 5′gamma(35)S triphosphate binding. Neurosci Lett. 2000, 280: 223-227. 10.1016/S0304-3940(00)00788-6.

  50. 50.

    Brys R, Josson K, Castelli MP, Jurzak M, Lijnen P, Gommeren W, Leysen JE: Reconstitution of the human 5-HT(1D) receptor-G-protein coupling: evidence for constitutive activity and multiple receptor conformations. Mol Pharmacol. 2000, 57: 1132-1141.

  51. 51.

    Newman-Tancredi A, Cussac D, Marini L, Touzard M, Millan MJ: h5-HT(1B) receptor-mediated constitutive Galphai3-protein activation in stably transfected Chinese hamster ovary cells: an antibody capture assay reveals protean efficacy of 5-HT. Br J Pharmacol. 2003, 138: 1077-1084. 10.1038/sj.bjp.0705140.

  52. 52.

    Kurrasch-Orbaugh DM, Parrish JC, Watts VJ, Nichols DE: A complex signaling cascade links the serotonin2A receptor to phospholipase A2 activation: the involvement of MAP kinases. J Neurochem. 2003, 86: 980-991. 10.1046/j.1471-4159.2003.01921.x.

  53. 53.

    Bhatnagar A, Sheffler DJ, Kroeze WK, Compton-Toth B, Roth BL: Caveolin-1 interacts with 5-HT2A serotonin receptors and profoundly modulates the signaling of selected Galphaq-coupled protein receptors. J Biol Chem. 2004, 279: 34614-34623. 10.1074/jbc.M404673200.

  54. 54.

    Millan MJ, la Cour Mannoury C, Chanrion B, Dupuis DS, Di Cara B, Audinot V, Cussac D, Newman-Tancredi A, Kamal M, Boutin JA, Jockers R, Marin P, Bockaert J, Muller O, Dekeyne A, Lavielle G: S32212, a novel serotonin type 2C receptor inverse agonist/alpha2-adrenoceptor antagonist and potential antidepressant: I. A mechanistic characterization. J Pharmacol Exp Ther. 2012, 340: 750-764. 10.1124/jpet.111.187468.

  55. 55.

    Odagaki Y, Kinoshita M, Toyoshima R: Functional activation of Galpha via serotonin (5-HT) and muscarinic acetylcholine M receptors assessed by guanosine-5-O-(3-[S]thio)triphosphate ([S]GTPgammaS) binding/immunoprecipitation in rat brain membranes. Eur J Pharmacol. 2014, 726C: 109-115. 10.1016/j.ejphar.2013.12.040.

  56. 56.

    Shi J, Zemaitaitis B, Muma NA: Phosphorylation of Galpha11 protein contributes to agonist-induced desensitization of 5-HT2A receptor signaling. Mol Pharmacol. 2007, 71: 303-313. 10.1124/mol.106.028241.

  57. 57.

    Shi J, Damjanoska KJ, Singh RK, Carrasco GA, Garcia F, Grippo AJ, Landry M, Sullivan NR, Battaglia G, Muma NA: Agonist induced-phosphorylation of Galpha11 protein reduces coupling to 5-HT2A receptors. J Pharmacol Exp Ther. 2007, 323: 248-256. 10.1124/jpet.107.122317.

  58. 58.

    Cussac D, Boutet-Robinet E, Ailhaud MC, Newman-Tancredi A, Martel JC, Danty N, Rauly-Lestienne I: Agonist-directed trafficking of signalling at serotonin 5-HT2A, 5-HT2B and 5-HT2C-VSV receptors mediated Gq/11 activation and calcium mobilisation in CHO cells. Eur J Pharmacol. 2008, 594: 32-38. 10.1016/j.ejphar.2008.07.040.

  59. 59.

    La Cour Mannoury C, Chaput C, Touzard M, Millan MJ: An immunocapture/scintillation proximity analysis of G alpha q/11 activation by native serotonin (5-HT)2A receptors in rat cortex: blockade by clozapine and mirtazapine. Synapse. 2009, 63: 95-105. 10.1002/syn.20587.

  60. 60.

    Launay JM, Birraux G, Bondoux D, Callebert J, Choi DS, Loric S, Maroteaux L: Ras involvement in signal transduction by the serotonin 5-HT2B receptor. J Biol Chem. 1996, 271: 3141-3147. 10.1074/jbc.271.6.3141.

  61. 61.

    Manivet P, Mouillet-Richard S, Callebert J, Nebigil CG, Maroteaux L, Hosoda S, Kellermann O, Launay JM: PDZ-dependent activation of nitric-oxide synthases by the serotonin 2B receptor. J Biol Chem. 2000, 275: 9324-9331. 10.1074/jbc.275.13.9324.

  62. 62.

    Chen Y, Baez M, Yu L: Functional coupling of the 5-HT2C serotonin receptor to G proteins in Xenopus oocytes. Neurosci Lett. 1994, 179: 100-102. 10.1016/0304-3940(94)90944-X.

  63. 63.

    Quick MW, Simon MI, Davidson N, Lester HA, Aragay AM: Differential coupling of G protein alpha subunits to seven-helix receptors expressed in Xenopus oocytes. J Biol Chem. 1994, 269: 30164-30172.

  64. 64.

    Hartman JL, Northup JK: Functional reconstitution in situ of 5-hydroxytryptamine2c (5HT2c) receptors with alphaq and inverse agonism of 5HT2c receptor antagonists. J Biol Chem. 1996, 271: 22591-22597. 10.1074/jbc.271.37.22591.

  65. 65.

    Alberts GL, Pregenzer JF, Im WB, Zaworski PG, Gill GS: Agonist-induced GTPgamma35S binding mediated by human 5-HT(2C) receptors expressed in human embryonic kidney 293 cells. Eur J Pharmacol. 1999, 383: 311-319. 10.1016/S0014-2999(99)00653-6.

  66. 66.

    Chang M, Zhang L, Tam JP, Sanders-Bush E: Dissecting G protein-coupled receptor signaling pathways with membrane-permeable blocking peptides. Endogenous 5-HT(2C) receptors in choroid plexus epithelial cells. J Biol Chem. 2000, 275: 7021-7029. 10.1074/jbc.275.10.7021.

  67. 67.

    Price RD, Weiner DM, Chang MS, Sanders-Bush E: RNA editing of the human serotonin 5-HT2C receptor alters receptor-mediated activation of G13 protein. J Biol Chem. 2001, 276: 44663-44668. 10.1074/jbc.M106745200.

  68. 68.

    Cussac D, Newman-Tancredi A, Duqueyroix D, Pasteau V, Millan MJ: Differential activation of Gq/11 and Gi(3) proteins at 5-hydroxytryptamine(2C) receptors revealed by antibody capture assays: influence of receptor reserve and relationship to agonist-directed trafficking. Mol Pharmacol. 2002, 62: 578-589. 10.1124/mol.62.3.578.

  69. 69.

    McGrew L, Chang MS, Sanders-Bush E: Phospholipase D activation by endogenous 5-hydroxytryptamine 2C receptors is mediated by Galpha13 and pertussis toxin-insensitive Gbetagamma subunits. Mol Pharmacol. 2002, 62: 1339-1343. 10.1124/mol.62.6.1339.

  70. 70.

    Okada M, Northup JK, Ozaki N, Russell JT, Linnoila M, Goldman D: Modification of human 5-HT(2C) receptor function by Cys23Ser, an abundant, naturally occurring amino-acid substitution. Mol Psychiatry. 2004, 9: 55-64. 10.1038/sj.mp.4001357.

  71. 71.

    Ponimaskin EG, Heine M, Joubert L, Sebben M, Bickmeyer U, Richter DW, Dumuis A: The 5-hydroxytryptamine(4a) receptor is palmitoylated at two different sites, and acylation is critically involved in regulation of receptor constitutive activity. J Biol Chem. 2002, 277: 2534-2546. 10.1074/jbc.M106529200.

  72. 72.

    Pindon A, van Hecke G, van Gompel P, Lesage AS, Leysen JE, Jurzak M: Differences in signal transduction of two 5-HT4 receptor splice variants: compound specificity and dual coupling with Galphas- and Galphai/o-proteins. Mol Pharmacol. 2002, 61: 85-96. 10.1124/mol.61.1.85.

  73. 73.

    Ponimaskin EG, Profirovic J, Vaiskunaite R, Richter DW, Voyno-Yasenetskaya TA: 5-Hydroxytryptamine 4(a) receptor is coupled to the Galpha subunit of heterotrimeric G13 protein. J Biol Chem. 2002, 277: 20812-20819. 10.1074/jbc.M112216200.

  74. 74.

    Pellissier LP, Barthet G, Gaven F, Cassier E, Trinquet E, Pin JP, Marin P, Dumuis A, Bockaert J, Baneres JL, Claeysen S: G protein activation by serotonin type 4 receptor dimers: evidence that turning on two protomers is more efficient. J Biol Chem. 2011, 286: 9985-9997. 10.1074/jbc.M110.201939.

  75. 75.

    Francken BJ, Josson K, Lijnen P, Jurzak M, Luyten WH, Leysen JE: Human 5-hydroxytryptamine(5A) receptors activate coexpressed G(i) and G(o) proteins in Spodoptera frugiperda 9 cells. Mol Pharmacol. 2000, 57: 1034-1044.

  76. 76.

    Francken BJ, Vanhauwe JF, Josson K, Jurzak M, Luyten WH, Leysen JE: Reconstitution of human 5-hydroxytryptamine5A receptor–G protein coupling in E. coli and Sf9 cell membranes with membranes from Sf9 cells expressing mammalian G proteins. Receptors Channels. 2001, 7: 303-318.

  77. 77.

    Noda M, Yasuda S, Okada M, Higashida H, Shimada A, Iwata N, Ozaki N, Nishikawa K, Shirasawa S, Uchida M, Aoki S, Wada K: Recombinant human serotonin 5A receptors stably expressed in C6 glioma cells couple to multiple signal transduction pathways. J Neurochem. 2003, 84: 222-232. 10.1046/j.1471-4159.2003.01518.x.

  78. 78.

    Baker LP, Nielsen MD, Impey S, Metcalf MA, Poser SW, Chan G, Obrietan K, Hamblin MW, Storm DR: Stimulation of type 1 and type 8 Ca2+/calmodulin-sensitive adenylyl cyclases by the Gs-coupled 5-hydroxytryptamine subtype 5-HT7A receptor. J Biol Chem. 1998, 273: 17469-17476. 10.1074/jbc.273.28.17469.

  79. 79.

    Kang H, Lee WK, Choi YH, Vukoti KM, Bang WG, Yu YG: Molecular analysis of the interaction between the intracellular loops of the human serotonin receptor type 6 (5-HT6) and the alpha subunit of GS protein. Biochem Biophys Res Commun. 2005, 329: 684-692. 10.1016/j.bbrc.2005.02.040.

  80. 80.

    Adham N, Zgombick JM, Bard J, Branchek TA: Functional characterization of the recombinant human 5-hydroxytryptamine7(a) receptor isoform coupled to adenylate cyclase stimulation. J Pharmacol Exp Ther. 1998, 287: 508-514.

  81. 81.

    Alberts GL, Chio CL, Im WB: Allosteric modulation of the human 5-HT(7A) receptor by lipidic amphipathic compounds. Mol Pharmacol. 2001, 60: 1349-1355.

  82. 82.

    Kvachnina E, Liu G, Dityatev A, Renner U, Dumuis A, Richter DW, Dityateva G, Schachner M, Voyno-Yasenetskaya TA, Ponimaskin EG: 5-HT7 receptor is coupled to G alpha subunits of heterotrimeric G12-protein to regulate gene transcription and neuronal morphology. J Neurosci. 2005, 25: 7821-7830. 10.1523/JNEUROSCI.1790-05.2005.

  83. 83.

    Kvachnina E, Dumuis A, Wlodarczyk J, Renner U, Cochet M, Richter DW, Ponimaskin E: Constitutive Gs-mediated, but not G12-mediated, activity of the 5-hydroxytryptamine 5-HT7(a) receptor is modulated by the palmitoylation of its C-terminal domain. Biochim Biophys Acta. 2009, 1793: 1646-1655. 10.1016/j.bbamcr.2009.08.008.

  84. 84.

    Houston C, Wenzel-Seifert K, Burckstummer T, Seifert R: The human histamine H2-receptor couples more efficiently to Sf9 insect cell Gs-proteins than to insect cell Gq-proteins: limitations of Sf9 cells for the analysis of receptor/Gq-protein coupling. J Neurochem. 2002, 80: 678-696. 10.1046/j.0022-3042.2001.00746.x.

  85. 85.

    Linder ME, Middleton P, Hepler JR, Taussig R, Gilman AG, Mumby SM: Lipid modifications of G proteins: alpha subunits are palmitoylated. Proc Natl Acad Sci U S A. 1993, 90: 3675-3679. 10.1073/pnas.90.8.3675.

  86. 86.

    Lambert NA, Johnston CA, Cappell SD, Kuravi S, Kimple AJ, Willard FS, Siderovski DP: Regulators of G-protein signaling accelerate GPCR signaling kinetics and govern sensitivity solely by accelerating GTPase activity. Proc Natl Acad Sci U S A. 2010, 107: 7066-7071. 10.1073/pnas.0912934107.

  87. 87.

    Bosch DE, Zielinski T, Lowery RG, Siderovski DP: Evaluating modulators of “Regulator of G-protein Signaling” (RGS) proteins. Curr Protoc Pharmacol. 2012, Chapter 2: Unit2 8-

  88. 88.

    Millan MJ, Marin P, Bockaert J, Mannoury la Cour C: Signaling at G-protein-coupled serotonin receptors: recent advances and future research directions. Trends Pharmacol Sci. 2008, 29: 454-464. 10.1016/j.tips.2008.06.007.

  89. 89.

    Moya PR, Berg KA, Gutierrez-Hernandez MA, Saez-Briones P, Reyes-Parada M, Cassels BK, Clarke WP: Functional selectivity of hallucinogenic phenethylamine and phenylisopropylamine derivatives at human 5-hydroxytryptamine (5-HT)2A and 5-HT2C receptors. J Pharmacol Exp Ther. 2007, 321: 1054-1061. 10.1124/jpet.106.117507.

  90. 90.

    Piva F, Giulietti M, Burini AB, Principato G: SpliceAid 2: a database of human splicing factors expression data and RNA target motifs. Hum Mutat. 2012, 33: 81-85. 10.1002/humu.21609.

  91. 91.

    Albert PR, Robillard L: G protein specificity: traffic direction required. Cell Signal. 2002, 14: 407-418. 10.1016/S0898-6568(01)00259-5.

Download references

Author information

Correspondence to Francesco Piva.

Additional information

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

MG, VV and FP performed the analyses and wrote the manuscript. GP, CB and BN conceived of the study, and participated in its design and coordination. All authors read and approved the final manuscript.

Electronic supplementary material

Additional file 1:Detailed information about G-protein isoforms. In this table all G-protein isoforms along with annotations extracted from UniProt and EntrezGene are shown. (XLS 51 KB)

Additional file 2:G-protein and serotonin receptor expression data in brain subtissues. In this table G-protein and serotonin receptor expression data extracted from different transcriptomic and proteomic databases are shown. (XLS 45 KB)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Keywords

  • G-Proteins
  • Serotonin receptors
  • Protein expression
  • Nomenclature